Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Crosses Above 50-Day Moving Average – Should You Sell?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) shares passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.02 and traded as high as $1.04. Lineage Cell Therapeutics shares last traded at $1.03, with a volume of 1,195,312 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Tuesday, July 14th. Four research analysts have rated the stock with a Buy rating. According to MarketBeat, Lineage Cell Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $6.25.

Lineage Cell Therapeutics Stock Up 3.3%

The company has a fifty day moving average price of $1.02 and a two-hundred day moving average price of $1.34.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.84 million. On average, sell-side analysts expect that Lineage Cell Therapeutics, Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Lineage Cell Therapeutics

Several large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Lineage Cell Therapeutics in the second quarter valued at about $17,275,000. Defender Capital LLC. increased its holdings in shares of Lineage Cell Therapeutics by 0.8% during the third quarter. Defender Capital LLC. now owns 6,648,899 shares of the company’s stock worth $6,354,000 after buying an additional 50,000 shares in the last quarter. Raffles Associates LP bought a new position in shares of Lineage Cell Therapeutics in the 2nd quarter valued at $6,809,000. Fifth Third Bancorp bought a new position in shares of Lineage Cell Therapeutics in the 1st quarter valued at $7,268,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of Lineage Cell Therapeutics by 210.6% during the 2nd quarter. Squarepoint Ops LLC now owns 444,774 shares of the company’s stock valued at $583,000 after acquiring an additional 301,584 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues.

Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration.